How toxic is ritexitinib?

Ritlecitinib (Ritlecitinib) is a drug targeting immune-mediated diseases. It is mainly used to treat autoimmune diseases such as psoriasis and rheumatoid arthritis. Although it has shown certain efficacy in clinical applications, the occurrence of toxicity and adverse reactions has also attracted widespread concern. Common adverse reactions of ritexitinib include headache, diarrhea, acne, rash, folliculitis, fever, atopic dermatitis, dizziness, and increased blood creatine phosphokinase. In addition, symptoms such as herpes zoster, erythrocytopenia, and stomatitis may occur in patients using this drug, which require close monitoring during clinical use.

In terms of safety, multiple warnings and precautions are clearly listed on the product label for rituxitinib. Among them, the most prominent is the warning about the risk of serious infection. Studies have shown that ritixitinib may cause immune suppression, thereby increasing the incidence of serious infections, including bacterial, fungal and viral infections. Along with the increased risk of these infections, patients may face higher rates of all-cause mortality, requiring detailed patient evaluation and monitoring during clinical use.

In addition to the risk of infection, ritixitinib is also associated with the occurrence of malignant tumors. Studies have pointed out that patients taking this drug may develop new or progression of pre-existing malignancies in some cases. Therefore, doctors need to carefully evaluate the patient's tumor history before prescribing and conduct relevant examinations regularly during treatment to detect potential problems in time.

Cardiovascular events are also an important safety concern with the use of ritexitinib. Clinical data suggests that the drug may increase the incidence of major cardiovascular events (MACE), including heart attacks, strokes, and more. This necessitates the use of this drug with extreme caution in patients at risk for cardiovascular disease and the need for cardiovascular health monitoring during all stages of treatment.